Scientific evidence

This section presents documents from researchers, study groups and international organizations, which contain the most rigorous scientific evidence on medicinal cannabis, consistent, in systematic reviews, meta-analyzes and randomized clinical trials.

In the report The Health Effects of Cannabis and Cannabinoids: the current state of evidence and Recommendations for Research, an expert and ad hoc committee of the National Academies of Sciences, Engineering and Medicine presents the following conclusions.

There is conclusive or substantial evidence that cannabis or cannabinoids are effective:

  • For the treatment of chronic pain in adults
  • Antiemetics in the treatment of chemotherapy-induced nausea and vomiting
  • To improve patient-reported multiple sclerosis spasticity symptoms

* CBD has been approved for refractory seizures (Lenox Gastau and Dravet syndrome)

There is moderate evidence that cannabis or cannabinoids are effective for:

• Improved short-term sleep outcomes in individuals with sleep disorders associated with obstructive sleep apnea syndrome, fibromyalgia, chronic pain, and multiple sclerosis.

There is limited evidence that cannabis or cannabinoids are effective for:

  • Increased appetite and decreased weight loss associated with HIV / AIDS
  • Improvement of multiple sclerosis spasticity symptoms
  • Improvement of Tourette syndrome symptoms
  • Improvement of anxiety symptoms

There is limited evidence of a statistical association between cannabinoids and improved outcomes

I.e. mortality, disability) after traumatic brain injury or intracranial hemorrhage.

There is limited evidence that cannabis or cannabinoids are not effective for:

  • Improvement of symptoms associated with dementia
  • Improved intraocular pressure associated with glaucoma
  • Reduction of depressive symptoms in people with chronic pain or multiple sclerosis

There is insufficient evidence or evidence to support or refute the conclusion that cannabis or cannabinoids are an effective treatment for:

  • Cancers, including glioma
  • Anorexia syndrome associated with cancer, cachexia and anorexia nervosa
  • Symptoms of irritable bowel syndrome
  • Spasticity in patients with paralysis due to spinal cord injury
  • Symptoms associated with amyotrophic lateral sclerosis
  • Chorea and certain neuropsychiatric symptoms associated with Huntington's disease
  • Motor system symptoms associated with Parkinson's disease or levodopa-induced dyskinesia
  • Distonía
  • Achieve abstinence from the use of addictive substances
  • Mental health outcomes in individuals with schizophrenia or schizophreniform psychosis